(Sharecast News) - AIM-listed biotech Physiomics has announced a new contract with client Numab Therapeutics to help development activities for the latter's oncology pipeline.
The contract, which is set to begin this month and last sometime in the third quarter, will see Physiomics develop a so-called mechanistic pharmacokinetic-pharmacodynamic modelling framework to...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE